Concerns raised last year over drug price deal delay
Exchequer unlikely to see any reprieve on prices until second half of 2016
The Department of Public Expenditure and Reform flagged concerns about delays in progressing a medicine price deal with big pharma a year ago.
The existing price deal that governs prices for the HSE’s €2 billion-plus spend on medicines was negotiated in 2012. With formal negotiations on a new deal yet to start, the exchequer is unlikely to see any reprieve on prices until the second half of 2016.
In a letter obtained under the Freedom...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Comment: Our reserves were not built to survive long Covid
The Asthma Society of Ireland wants to end deaths from the condition by 2030, but the prolonged pandemic has heaped pressure on its services
Design for Life: My father refuses to get the Covid-19 vaccine
Psychotherapist Siobhán Murray advises a reader on how to talk to her recently widowed father about loss, loneliness and his fear of taking a Covid-19 vaccine
Susan O’Keeffe: We must put women’s healthcare out of reach of the Church for good
Despite the progress and promises made in recent years, we risk going backwards if the state allows the Sisters of Charity have any part in the new National Maternity Hospital
Covid-19: India’s crisis brings vaccine access inequality into sharp focus
Advocates for global access to coronavirus jabs are calling for a more radical approach to their rollout by waiving intellectual property rights to the vaccines